PROCEPT BioRobotics Corp (PRCT)
PROCEPT BioRobotics Corp (PRCT) from its SEC filings: 2025 revenue $308.1 million (+37% vs the year before), net margin -0%, free cash flow -$58.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Revenue (2025) | $308.1 million |
| Revenue growth | +37% |
| Net income | -$95,572 |
| Net margin | -0.0% |
| Free cash flow | -$58.3 million |
| Diluted EPS | $-1.72 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +19% |
| Cash | $227.9 million |
| Long-term debt | $51.7 million |
| Share count, 1 year | +3% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.